Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 18 recruiting now full pipeline

Menopause: full-pipeline trial registry

18 of 55 indexed Menopause trials are currently recruiting.

Corpus placement: #254 of 28,707 conditions by registered trial count.

55 US clinical trials · 18 currently recruiting · #254 of 28,707 conditions by registered trial count

Menopause: 55 US clinical trials tracked, 18 recruiting.

Menopause is the subject of 55 registered US clinical trials on ClinicalTrials.gov, 18 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is University of Colorado, Denver, running 6 of these trials.

Enrollment posture brief

Registry condition menopause

OPEN 18 | RECR 33% | LATE 12 | EARLY 17 | RANK #254 | SPON 6

Nearest open-share peer: Non-alcoholic Fatty Liver Disease (33% recruiting · 58 trials)

Colorectal Neoplasms41.8%Down Syndrome38.2%Menopause (this)33%Constipation27.3%Brain and Central Nervous Sy1.8%
Open-enrollment share among volume-matched conditions near Menopause

Menopause lists 18 open slots (33% of 55 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Menopause on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Menopause is recruiting below its size-band peers.

    18 of 55 indexed trials (32.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Menopause trials is spread across many organizations.

    University of Colorado, Denver accounts for 6 of 55 trials (10.9%). 38 distinct sponsors appear on at least one study for this condition label.

  3. Most Menopause trials plan to enrol fewer than 100 people.

    Median target enrolment is 66 among the 55 trials that report a genuine target (sentinel values excluded). 33 of those (60%) plan for fewer than 100 participants.

  4. Menopause research is mostly interventional.

    49 interventional and 6 observational studies make up this index (89.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 213Phase 33Phase 49

Open and recent trials

55 total, page 1 of 2

RECRUITING 500,000 participants

Apple Women's Health Study

Apple

NCT04196595

RECRUITING 160 participants

Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women

University of Minnesota

NCT04439370

RECRUITING NA 120 participants

Hot Flashes and Neurovascular Function in Women

Mayo Clinic

NCT05193968

RECRUITING Phase 2 104 participants

Effects of Hemp-Derived Cannabinoids on Menopause Symptoms

Washington State University

NCT07393672

RECRUITING Phase 4 100 participants

Cardiometabolic Consequences of the Loss of Ovarian Function

University of Colorado, Denver

NCT06264882

RECRUITING Phase 2 100 participants

Impact of Cannabinoids on Menopause Symptoms

Washington State University

NCT06831916

RECRUITING 80 participants

Menopause Transition, Sex Hormone Deficiency and Autonomic and Vascular Function

University of Minnesota

NCT06490146

RECRUITING Early Phase 1 75 participants

Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms

University of Missouri-Columbia

NCT06787066

RECRUITING Early Phase 1 75 participants

Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia

University of Missouri-Columbia

NCT06417177

RECRUITING Phase 4 61 participants

Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes

Brigham and Women's Hospital

NCT05593653

RECRUITING 60 participants

The Cardiovascular Impact of Hot Flushes

University of Minnesota

NCT05251324

RECRUITING NA 51 participants

Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study

SF Research Institute

NCT06716554

RECRUITING NA 40 participants

Exercise Training Intensity and Nitrate Supplementation in Post-Menopausal Females

University of Virginia

NCT06480695

RECRUITING NA 30 participants

Improving Sympathetic Activity, Hot Flashes, and Sleep in Midlife Women Using Inspiratory Muscle Strength Training

Mayo Clinic

NCT06743269

RECRUITING Phase 2 30 participants

The Anabolic Effect of Testosterone on Pelvic Floor Muscles

Brigham and Women's Hospital

NCT06111209

RECRUITING NA 30 participants

Depression, Aging, Stress and Heart Health Study

University of North Carolina, Chapel Hill

NCT05570721

RECRUITING Phase 4 24 participants

Role of Menopause in Thermoregulation

Penn State University

NCT06798571

RECRUITING NA 20 participants

Choline Dose Ranging in Postmenopausal Women

Julie Dumas

NCT06924541

ACTIVE NOT RECRUITING Phase 2 100 participants

PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition

Roberta Brinton

NCT05664477

ACTIVE NOT RECRUITING Phase 4 55 participants

Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)

University of Colorado, Denver

NCT05057546

ACTIVE NOT RECRUITING Early Phase 1 22 participants

MitoQ and Exercise Effects on Vascular Health

University of Colorado, Denver

NCT05686967

COMPLETED Phase 3 1,845 participants

A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms

TherapeuticsMD

NCT01942668

COMPLETED NA 500 participants

Radicle Revive 24: A Study of Health and Wellness Products on Menopausal Health and Related Health Outcomes

Radicle Science

NCT06749288

COMPLETED Phase 3 450 participants

Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women

Wyeth is now a wholly owned subsidiary of Pfizer

NCT00369434

COMPLETED NA 410 participants

MyMenoPlan: Online Resource for Improving Women's Menopause Knowledge and Informed Decision-making

University of California, San Diego

NCT05299983

COMPLETED NA 355 participants

MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation

Fred Hutchinson Cancer Center

NCT01178892

COMPLETED Phase 2 350 participants

Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women

Solvay Pharmaceuticals

NCT00141570

COMPLETED Phase 2 203 participants

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

Warner Chilcott

NCT02670785

COMPLETED Phase 2 172 participants

Perimenopausal Estrogen Replacement Therapy Study

University of North Carolina, Chapel Hill

NCT01308814

COMPLETED NA 154 participants

Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes

Christopher Drake

NCT01933295

COMPLETED NA 150 participants

Development and Evaluation of a Hormone Replacement Therapy Decision-Aid

US Department of Veterans Affairs

NCT00012909

COMPLETED NA 150 participants

Caria: Digital Intervention for Menopause Symptom

University of Illinois at Chicago

NCT04882982

COMPLETED Phase 2 125 participants

Hormone Replacement in Menopausal Women With Epilepsy

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00027209

COMPLETED Phase 2 112 participants

Use of Black Cohosh and Red Clover for the Relief of Menopausal Symptoms

National Center for Complementary and Integrative Health (NCCIH)

NCT00066144

COMPLETED Phase 2 105 participants

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

Fervent Pharmaceuticals

NCT05312567

COMPLETED Early Phase 1 100 participants

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

University of Colorado, Denver

NCT02042196

COMPLETED Phase 2 96 participants

Research Investigation of Soy and Estrogen

University of Illinois at Chicago

NCT00997893

COMPLETED 72 participants

Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure

National Eye Institute (NEI)

NCT00471731

COMPLETED 66 participants

Metabolic and Psychological Changes Associated With Menopause Among Women With HIV

Massachusetts General Hospital

NCT01142817

COMPLETED Phase 4 60 participants

Hormone Estradiol Replacement Therapy Additional Herbals

Trieu, Nguyen Thi, M.D.

NCT02618148

COMPLETED NA 53 participants

Following Lipectomy to Understand Adipose Tissue Re-accumulation

University of Colorado, Denver

NCT00995631

COMPLETED Phase 2 50 participants

Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy

Dana-Farber Cancer Institute

NCT00165204

COMPLETED Phase 3 50 participants

Therapy to Prevent Sexual Pain in Breast Cancer Survivors

OHSU Knight Cancer Institute

NCT01539317

COMPLETED Phase 4 40 participants

Estrogen Variability and Irritability During the Menopause Transition

University of North Carolina, Chapel Hill

NCT05388656

COMPLETED NA 40 participants

Pilot Study of Stellate Ganglion Injection to Provide Relief From Hot Flushes

Northwestern University

NCT00992914

COMPLETED NA 38 participants

Reducing the Experience of Menopausal Symptoms Through Temperature

Wake Forest University Health Sciences

NCT03937466

COMPLETED NA 30 participants

The Role of the Gut Microbiota in Estrogen Metabolism and Dietary Flax as a Potential Modulator.

Colorado State University

NCT03183102

COMPLETED Phase 4 29 participants

Duloxetine for Menopausal Depression

Massachusetts General Hospital

NCT01117857

COMPLETED Phase 4 25 participants

Effect of Nuvigil on Fatigue

Massachusetts General Hospital

NCT01460628

COMPLETED Phase 2 24 participants

A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis

University of California, San Francisco

NCT02710214

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 13
Phase 3 3
Phase 4 9

Named interventions

Most-linked intervention names on Menopause records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
11 trials
Placebo Dietary supplement
4 trials
Estradiol Drug
3 trials
MyMenoPlan Other
1 trials
Topical liquid lidocaine Drug
1 trials
Usual Activity Behavioral
1 trials
FP-101 Drug
1 trials
Superficial subcutaneous injection Procedure
1 trials

US sites by state

Facility locations filed on Menopause trials. A trial with sites in several states counts in each.

Colorado 10 trials
California 10 trials
Massachusetts 7 trials
North Carolina 6 trials
Minnesota 5 trials
Illinois 5 trials
Arizona 5 trials
Washington 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Menopause page

55 registered trials, 18 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Menopause condition card totals 55 registered trials; most-linked intervention Placebo; top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.